Efficacy of extended infusion of ß-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial
Por:
Laporte-Amargos, J, Carmona-Torre, F, Huguet, M, Puerta-Alcalde, P, Rigo-Bonnin, R, Ulldemolins, M, Arnan, M, Pozo, JLD, Torrent, A, Garcia-Vidal, C, Pallarès, N, Tebé, C, Muñoz, C, Tubau, F, Padullés, A, Sureda, AM, Carratalà, J and Gudiol, C
Publicada:
1 feb 2025
Ahead of Print:
1 ene 2025
Resumen:
Objectives: The efficacy of extended infusions (EI) of beta-lactam antibiotics for optimising outcomes in febrile neutropenia is unclear. We assessed whether the administration of beta-lactams was more effective in EI than in intermittent infusion (II) for the treatment of febrile neutropenia.
Methods: We performed a randomized, open-label, superiority clinical trial of patients with febrile neutropenia at four Spanish university hospitals. Patients undergoing haematopoietic stem cell transplantation or with acute leukaemia receiving chemotherapy who required empirical antibiotic treatment for febrile neutropenia were randomly assigned (1:1) to receive EI of beta-lactam or II after a first dose in bolus. The choice of antipseudomonal beta-lactam was left to the discretion of the attending physician. The primary endpoint was treatment success at day 5, defined as defervescence without modifying the antibiotic treatment. Secondary endpoints included adverse events, attainment of the pharmacokinetic/ pharmacodynamic target of 50%, 75%, and 100%GuT , MIC, and 30-day mortality.
Results: From November 19, 2019 to June 22, 2022, 295 patients were screened for eligibility, of whom 150 were randomly assigned to receive EI (n = 77) or II (n = 73) of the antipseudomonal beta-lactam of choice. In the intention-to-treat analysis, treatment success at day 5 was achieved in 39/77 patients 4.7; p 0.17). The pharmacokinetic/pharmacodynamic targets of 75% and 100% GuT , MIC for empirical treatment were achieved more frequently in the EI group. No statistically significant differences were found between groups in terms of adverse events or 30-day mortality.
Discussion: Our findings do not support the routine use of empirical EI of [3-lactams in febrile neutropenia. Further studies should consider the clinical heterogeneity of febrile neutropenia and focus on patients with sepsis or septic shock and microbiologically documented infections, particularly those with infections caused by microorganisms less susceptible to [3-lactams. Julia Laporte-Amargos, Clin (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
Filiaciones:
Laporte-Amargos, J:
Bellvitge Univ Hosp, Dept Infect Dis, Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Barcelona, Spain
Carmona-Torre, F:
Clin Univ Navarra, Navarra Inst Hlth Res IdiSNA, Dept Infect Dis, Pamplona, Spain
Huguet, M:
Bellvitge Univ Hosp, Dept Infect Dis, Feixa Llarga S-N, Lhospitalet De Llobregat 08907, Barcelona, Spain
Hosp Germans Trias i Pujol, Josep Carreras Leukemia Res Inst, Inst Catala Oncol Badalona, Dept Clin Haematol, Badalona, Spain
:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS, Infect Dis Dept, LHospitalet De Llobregat, Barcelona, Spain
Rigo-Bonnin, R:
Bellvitge Univ Hosp, Bellvitge Biomed Res Inst IDIBELL, Dept Clin Lab, Lhospitalet De Llobregat, Barcelona, Spain
Arnan, M:
Bellvitge Biomed Res Inst IDIBELL, Inst Catala Oncol Hosp, Dept Clin Haematol, Lhospitalet De Llobregat, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Pozo, JLD:
Clin Univ Navarra, Navarra Inst Hlth Res IdiSNA, Dept Infect Dis, Pamplona, Spain
Clin Univ Navarra, Dept Clin Microbiol, Pamplona, Spain
Torrent, A:
Hosp Germans Trias i Pujol, Josep Carreras Leukemia Res Inst, Inst Catala Oncol Badalona, Dept Clin Haematol, Badalona, Spain
Garcia-Vidal, C:
Hosp Clin Barcelona, Inst Invest Biomed August Pi Sunyer IDIBAPS, Infect Dis Dept, LHospitalet De Llobregat, Barcelona, Spain
Pallarès, N:
Bellvitge Biomed Res Inst IDIBELL, Biostat Unit, LHospitalet De Llobregat, Barcelona, Spain
Tubau, F:
Bellvitge Univ Hosp, Dept Microbiol, Lhospitalet De Llobregat, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Resp CIBERES, Madrid, Spain
Sureda, AM:
Bellvitge Biomed Res Inst IDIBELL, Inst Catala Oncol Hosp, Dept Clin Haematol, Lhospitalet De Llobregat, Barcelona, Spain
Carratalà, J:
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecc CIBERINF, Madrid, Spain
Bellvitge Biomed Res Inst IDIBELL, Lhospitalet De Llobregat, Barcelona, Spain
Gudiol, C:
Bellvitge Biomed Res Inst IDIBELL, Inst Catala Oncol Hosp, Dept Pharm, Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Infecc CIBERINF, Madrid, Spain
Bellvitge Biomed Res Inst IDIBELL, Lhospitalet De Llobregat, Barcelona, Spain
Inst Catala Oncol, Barcelona, Spain
Bellvitge Univ Hosp, Dept Pharm, Lhospitalet De Llobregat, Barcelona, Spain
Bronze
|